Literature DB >> 19877731

Clinical aspects of invasive candidiasis in the surgical patient.

Gabriele Sganga1.   

Abstract

Improvements in post-surgical care have led to decreased mortality, but to an increased number of critically ill surgical patients at high risk of fungal colonization and invasive disease. Use of catheters, enteral nutrition, antibacterials and haemodialysis add to the risk. Although Candida albicans remains the most common species causing invasive candidiasis in the post-surgical setting, there has been an increase in the prevalence of non-albicans species associated with the increased use of fluconazole prophylaxis in surgical intensive care units. The prompt diagnosis of candidiasis is complicated by a lack of specific clinical symptoms and difficulties in laboratory diagnosis; therefore, it is vital to recognize at-risk patients and initiate therapy promptly in these individuals. While Candida scoring systems to identify at-risk patients have been developed, these need to be validated in prospective interventional trials. Newer azole and echinocandin antifungal agents have expanded the range of available treatments, and prophylactic antifungal therapy in at-risk, critically ill surgical patients has been shown to be effective.

Entities:  

Mesh:

Year:  2009        PMID: 19877731     DOI: 10.2165/11315600-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  28 in total

1.  Clinical trials of antifungal prophylaxis among patients undergoing surgery.

Authors:  Thierry Calandra; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2004-10-15       Impact factor: 9.079

Review 2.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

Authors:  A M Rentz; M T Halpern; R Bowden
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

4.  Clinical significance of Candida isolated from peritoneum in surgical patients.

Authors:  T Calandra; J Bille; R Schneider; F Mosimann; P Francioli
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

Review 5.  Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.

Authors:  J L Vincent; E Anaissie; H Bruining; W Demajo; M el-Ebiary; J Haber; Y Hiramatsu; G Nitenberg; P O Nyström; D Pittet; T Rogers; P Sandven; G Sganga; M D Schaller; J Solomkin
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

6.  Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients.

Authors:  Hervé Dupont; Catherine Paugam-Burtz; Claudette Muller-Serieys; Lisiane Fierobe; Denis Chosidow; Jean-Pierre Marmuse; Jean Mantz; Jean-Marie Desmonts
Journal:  Arch Surg       Date:  2002-12

7.  Temporal assessment of Candida risk factors in the surgical intensive care unit.

Authors:  P S McKinnon; D A Goff; J W Kern; J W Devlin; J F Barletta; S J Sierawski; A C Mosenthal; P Gore; A J Ambegaonkar; T J Lubowski
Journal:  Arch Surg       Date:  2001-12

8.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Candida sepsis in surgical patients.

Authors:  P J Eubanks; C de Virgilio; S Klein; F Bongard
Journal:  Am J Surg       Date:  1993-12       Impact factor: 2.565

Review 10.  Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

Authors:  Benoît P Guery; Maiken C Arendrup; Georg Auzinger; Elie Azoulay; Márcio Borges Sá; Elizabeth M Johnson; Eckhard Müller; Christian Putensen; Coleman Rotstein; Gabriele Sganga; Mario Venditti; Rafael Zaragoza Crespo; Bart Jan Kullberg
Journal:  Intensive Care Med       Date:  2008-10-30       Impact factor: 17.440

View more
  2 in total

1.  Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Authors:  Pasquale De Bellis
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  "De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany.

Authors:  Anke van Engen; Montserrat Casamayor; Soyoung Kim; Maureen Watt; Isaac Odeyemi
Journal:  Clinicoecon Outcomes Res       Date:  2017-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.